Key Takeaways
- BPH is non-cancerous prostate enlargement; prostate cancer involves malignant cell growth — they are separate conditions.
- Both conditions can cause similar urinary symptoms, making professional diagnosis essential.
- BPH does not increase your risk of developing prostate cancer.
- Prostate cancer is often asymptomatic in early stages, making routine screening critical for men over 50.
- PSA blood tests and digital rectal exams are used to screen for both conditions but cannot definitively diagnose either.
- Early detection of prostate cancer significantly improves treatment outcomes.
Option A
Benign Prostatic Hyperplasia (BPH)
The common, non-cancerous prostate enlargement.
Best for: Understanding urinary symptoms caused by age-related prostate growth that is not life-threatening.
Option B
Prostate Cancer
The malignant condition requiring timely detection and treatment.
Best for: Recognizing when prostate changes may signal a serious condition that demands immediate medical evaluation.
If you're experiencing urinary symptoms like weak stream or frequent nighttime urination
See a doctor for evaluation of both BPH and Prostate Cancer
Overlapping symptoms mean self-diagnosis is unreliable. A urologist can determine the actual cause and recommend appropriate management.
If you are over 50 and have no current symptoms
Prostate Cancer Screening
Early-stage prostate cancer is often silent. Discuss PSA screening with your doctor to catch any malignancy before symptoms emerge.
If you've been diagnosed with BPH and are worried about cancer risk
BPH management with regular monitoring
BPH does not cause or convert to prostate cancer, but ongoing monitoring ensures any independent cancer development is caught early.
If you have a family history of prostate cancer
Prostate Cancer Screening starting at age 40–45
Family history significantly elevates prostate cancer risk. Earlier and more frequent screening is generally recommended in these cases.
What Are BPH and Prostate Cancer?
The prostate is a walnut-sized gland that sits below the bladder and surrounds the urethra. As men age, two of the most common conditions affecting this gland are benign prostatic hyperplasia (BPH) and prostate cancer. While both involve changes to prostate tissue, they are fundamentally different in nature, risk, and how they're managed.
BPH is a non-cancerous enlargement of the prostate. As the gland grows, it can squeeze the urethra and disrupt normal urinary flow. It is extraordinarily common — by age 60, roughly half of men show signs of BPH, and by age 85 that figure approaches 90%, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
Prostate cancer occurs when cells in the prostate begin to grow and divide abnormally, forming tumors that can potentially spread beyond the gland. It is the second most common cancer among American men. Crucially, most prostate cancers grow slowly, though some are aggressive and require prompt treatment.
For a broader look at how the prostate changes throughout a man's life, see Prostate Health Across the Decades.
Symptoms: Where They Overlap and Diverge
One of the most clinically important challenges with these two conditions is that their symptoms can look nearly identical — at least in certain stages.
Shared Symptoms
- Frequent or urgent need to urinate
- Weak or interrupted urine stream
- Difficulty starting urination
- Feeling that the bladder hasn't fully emptied
- Increased nighttime urination (nocturia)
Symptoms More Specific to Prostate Cancer
- Blood in urine or semen
- Pelvic discomfort or bone pain (in advanced disease)
- Erectile dysfunction (though this has many causes)
A key distinction: early-stage prostate cancer frequently produces no symptoms at all. BPH, by contrast, almost always makes itself known through urinary complaints. This is why relying on symptoms alone to rule out cancer is medically risky.
| Criterion | BPH | Prostate Cancer |
|---|---|---|
| Nature | Non-cancerous cell overgrowth | Malignant cell growth |
| Life-threatening | No | Can be, if untreated |
| Urinary symptoms | Common and prominent | Often absent early on |
| Can spread to other organs | No | Yes, in advanced stages |
| Primary screening tool | PSA, DRE, symptom score | PSA, DRE, biopsy |
| Increases cancer risk | No | N/A |
| Common treatment | Medication or procedure | Surveillance, surgery, or radiation |
Diagnosis and Screening
Because symptoms overlap so significantly, accurate diagnosis requires clinical testing. The two primary tools physicians use are:
- PSA (Prostate-Specific Antigen) blood test: Elevated PSA levels can indicate BPH, prostate cancer, or other prostate conditions like prostatitis. Elevated PSA does not confirm cancer — it signals the need for further investigation.
- Digital Rectal Exam (DRE): A physician physically examines the prostate for irregularities in size, shape, or texture.
If findings suggest cancer, additional steps such as an MRI or a prostate biopsy are typically used to confirm the diagnosis. BPH is generally confirmed through symptom assessment, urinary flow studies, and imaging.
Current guidelines from the American Cancer Society recommend that men at average risk discuss PSA screening with their doctor starting at age 50, while men with higher risk — such as those with a first-degree relative diagnosed before 65, or Black men who face statistically higher rates of prostate cancer — should have that conversation starting at age 40 to 45.
~90%
Men with BPH signs by age 85
According to the National Institute of Diabetes and Digestive and Kidney Diseases, BPH is nearly universal among older men.
1 in 8
American men diagnosed with prostate cancer in their lifetime
The American Cancer Society estimates this lifetime risk, making prostate cancer the second most common cancer in American men.
>99%
5-year relative survival rate for localized prostate cancer
The American Cancer Society reports that when prostate cancer is caught before it spreads, the 5-year survival rate is greater than 99%.
Treatment Approaches
Treatment pathways for BPH and prostate cancer differ considerably based on the condition's nature and severity.
BPH Treatment
Mild BPH may require only lifestyle modifications and monitoring — sometimes called watchful waiting. Moderate-to-severe cases may involve medications such as alpha-blockers (which relax muscles around the urethra) or 5-alpha reductase inhibitors (which reduce prostate size). Minimally invasive procedures and surgery are options when medications prove insufficient.
Prostate Cancer Treatment
Treatment depends heavily on the cancer's stage and aggressiveness. Low-risk, slow-growing cancers may be managed with active surveillance — regular monitoring rather than immediate intervention. Higher-risk or more advanced cancer may require surgery (radical prostatectomy), radiation therapy, hormone therapy, chemotherapy, or a combination. The decision is made collaboratively between the patient and their care team, factoring in age, health status, and personal preferences.
This article is for general health information and education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for any health concerns or before making any medical decisions.